Health Technology Assessment… Value, Affordability, and… Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research Read more
Drug Development/R&D Economics of Innovation Competition R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C Read more
Economics of Innovation Health Policy and Regulation Establishing a Reasonable Price for an Orphan Drug Read more
Indication-Based Pricing Economics of Innovation Health Policy and Regulation Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals Read more
Measuring and Valuing Outcomes Cancer Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology Read more
Emerging Markets Economics of Innovation Health Policy and Regulation A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List” Read more
Indication-Based Pricing Economics of Innovation Health Policy and Regulation The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries Read more
Economics of Innovation Pharmaceutical Industry The UK Biotech Sector and Brexit: Past Performance and Future Prospects Read more
Filter results by Theme Select the product option you would like to filter Theme Economics of Innovation Measuring and Valuing Outcomes Policy, Organisation and Incentives in Health Systems Value, Affordability, and Decision Making Topic Select the product option you would like to filter Topic Antimicrobial Resistance (AMR) Biosimilars Cell and Gene Therapies Chronic Diseases Combination Therapies COVID-19 Research Dementia Digital Health Drug Development/R&D Emerging Markets EQ-5D and PROMs Health Care Systems Health Data and Statistics Health Technology Assessment (HTA) Indication-Based Pricing Innovation Policy Prize OHE Consulting Precision Medicine Prevention Real World Evidence (RWE) Research Sustainability Use of Medicines Vaccines Value-Based Pricing Tag Select the product option you would like to filter Tag Adult Immunisation Alzheimer's Broader value and societal perspective in HTA Budget Impact Analysis Cancer Cardiovascular Disorders Care-givers Caring burden Cervical Cancer Clinical Outcomes Commentary Competition Dermatology Determining Value Diversity of Supply Drug Shortages Economic Evaluation Egypt Epidemiology and Public Health Epilepsy Gene therapies Generics Greece Haemophilia Health Policy and Regulation Health System Resiliency Healthcare Delivery Healthcare Expenditure Healthcare Funding Healthcare System Pressure (HCSP) India Infectious Diseases Inflation Reduction Act Injury and Trauma Innovation Israel Market Access Mental Health Pharmaceutical Industry Plant-based Policy Analysis Pricing and Reimbursement Primary Care Quality of Care Quality of Life Rare and Orphan Diseases Research Funding Resource Allocation Respiratory Cost Calculator Saudi Arabia Slovak Republic Societal preferences Supply of Medicine Türkiye Unmet Need Vaccines Value based pricing Webinar Date 1 Select the product option you would like to filter Date Clear Filter Date From Month From Year From Date To Month To Year To January February March April May June July August September October November December total + el.scrollHeight*2, 0) + 'px'" style=""> Today - 2020 2020 2021 2022 2023 2024 2025 2019 - 2010 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2009 - 2000 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 1999 - 1990 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 1989 - 1980 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1979 - 1970 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1969 - 1960 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 January February March April May June July August September October November December total + el.scrollHeight*2, 0) + 'px'" style=""> Today - 2020 2020 2021 2022 2023 2024 2025 2019 - 2010 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2009 - 2000 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 1999 - 1990 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 1989 - 1980 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1979 - 1970 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1969 - 1960 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 Author Select the product option you would like to filter Author Search authors Rosanna Tarricone Edwine Barasa Angela Kairu Neil Mcauslane Adam Raymakers Kiran Bhatti Kelsey Moore Meindert Boysen Pedro Pita Barros Andrew Briggs Content Type Select the product option you would like to filter Content Type news story insight events podcast bulletin publications Reset Filters Cell and Gene Therapies Value, Affordability, and… Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose? Read more © NCI/Unsplash Measuring and Valuing Outcomes When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies Read more Health Technology Assessment… Measuring and Valuing Outcomes Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies Read more © WellcomeCollection News December 2021 OHE Thanks Trustees for Their Service Read more Bulletin December 2021 2021: A course in accelerated learning Read more Insight December 2021 OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates Read more News November 2021 Opportunity Cost in Health Care: a Favourite Research Topic for OHE Read more Bulletin November 2021 Unmet needs: Adressing gaps and backlogs Read more News October 2021 We have launched OHE Bulletin, a new monthly newsletter Read more Bulletin October 2021 Perspective is everything Read more Past Event OHE Webinar October 2021 The Role of Unmet Need in Pharmaceutical Innovation Read more Past Event Annual Lecture September 2021 Virtual OHE Annual Lecture 2021: Do Patents Work? Evidence from Pharmaceutical Innovation Read more Insight September 2021 Does the New CBO Report Change Anything? Read more Insight September 2021 Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking Read more Insight September 2021 CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation Read more Insight September 2021 The CBO Doesn’t Understand Investors Read more Load More 00 11 12 13 14 15 16 17 18 19 00
Cell and Gene Therapies Value, Affordability, and… Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose? Read more © NCI/Unsplash
Measuring and Valuing Outcomes When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies Read more
Health Technology Assessment… Measuring and Valuing Outcomes Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies Read more © WellcomeCollection
Insight December 2021 OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates Read more
Past Event Annual Lecture September 2021 Virtual OHE Annual Lecture 2021: Do Patents Work? Evidence from Pharmaceutical Innovation Read more
Insight September 2021 Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking Read more